FDMT - 4D Molecular Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.00
DETAILS
HIGH:
$33.00
LOW:
$33.00
MEDIAN:
$33.00
CONSENSUS:
$33.00
UPSIDE:
277.14%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Revenue | 85.2 | 0.0 | 20.7 | 3.1 | 18.0 | 13.6 | 7.0 | 14.1 | 5.8 |
| Cost of Revenue | 7.6 | 0 | 97.1 | 80.3 | 61.4 | 53.0 | 38.7 | 18.4 | 13.6 |
| Gross Profit | 77.6 | 0.0 | (76.4) | (77.1) | (43.3) | (39.4) | (31.7) | (4.2) | (7.8) |
| Operating Expenses | |||||||||
| R&D Expenses | 195.7 | 141.3 | 97.1 | 80.3 | 61.4 | 53.0 | 43.9 | 18.4 | 13.6 |
| SG&A Expenses | 49.1 | 46.6 | 36.5 | 32.9 | 28.0 | 17.2 | 13.9 | 6.2 | 3.5 |
| Other Expenses | (7.6) | 0 | (97.1) | (80.3) | (61.4) | (53.0) | (38.7) | (0.0) | (0.0) |
| Operating Expenses | 237.1 | 187.9 | 36.5 | 32.9 | 28.0 | 17.2 | 19.0 | 24.5 | 17.1 |
| Operating Income | |||||||||
| Operating Income | (159.5) | (187.8) | (112.9) | (110.0) | (71.3) | (56.7) | (50.8) | (10.4) | (11.3) |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 19.5 | 27.1 | 12.2 | 2.6 | 0.1 | 0.2 | 1.5 | 0.8 | 0.1 |
| Profitability | |||||||||
| EBITDA | (151.9) | (181.1) | (108.7) | (107.6) | (69.8) | (55.2) | (44.6) | (9.7) | (10.6) |
| EBIT | (159.5) | (187.8) | (112.9) | (110.0) | (71.3) | (56.7) | (45.6) | (10.4) | (11.3) |
| Income Before Tax | (140.1) | (160.9) | (100.8) | (107.5) | (71.3) | (56.7) | (49.3) | (9.6) | (11.2) |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (0.1) |
| Net Income | (140.1) | (160.9) | (100.8) | (107.5) | (71.3) | (56.7) | (49.3) | (9.6) | (11.2) |
| Per Share Data | |||||||||
| EPS (Basic) | -2.42 | -2.98 | -2.58 | -3.12 | -2.46 | -2.12 | -2.00 | -0.76 | -0.76 |
| EPS (Diluted) | -2.42 | -2.98 | -2.58 | -3.12 | -2.46 | -2.12 | -2.00 | -0.76 | -0.76 |
| Shares Outstanding | 57.9 | 53.9 | 39.1 | 32.4 | 27.7 | 26.7 | 26.5 | 12.5 | 14.8 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Assets | |||||||||
| Cash & Cash Equivalents | 60.2 | 149.3 | 249.1 | 52.4 | 153.0 | 276.7 | 49.7 | 91.8 | 23.9 |
| Short-Term Investments | 342.4 | 275.5 | 39.1 | 161.2 | 94.8 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0.7 | 0.0 | 1.5 | 1.0 | 1.1 | 0.3 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 10.5 | 10.1 | 8.4 | 6.3 | 0 | 4.4 | 0 | 0 | 0 |
| Total Current Assets | 413.1 | 434.9 | 296.6 | 220.5 | 256.3 | 282.7 | 52.5 | 94.1 | 24.5 |
| Non-Current Assets | |||||||||
| Property, Plant & Equipment | 33.0 | 40.6 | 31.7 | 35.3 | 29.0 | 5.1 | 5.0 | 2.5 | 2.7 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 80.6 | 11.0 | 4.9 | 67.7 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 120.6 | 4.3 | 0.7 | 1.1 | 0.6 | 0.6 | 0.7 | 0.4 | 0.1 |
| Total Non-Current Assets | 153.6 | 125.5 | 43.3 | 41.3 | 97.2 | 5.7 | 5.7 | 2.9 | 2.8 |
| Total Assets | 566.7 | 560.4 | 339.9 | 261.8 | 353.5 | 288.3 | 58.2 | 97.0 | 27.3 |
| Current Liabilities | |||||||||
| Account Payables | 11.2 | 4.4 | 3.5 | 3.3 | 4.8 | 1.8 | 1.7 | 1.0 | 0.5 |
| Short-Term Debt | 5.6 | 0 | 0 | 2.7 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0.4 | 0.3 | 0.3 | 0.9 | 2.6 | 6.6 | 5.9 | 4.9 | 4.4 |
| Other Current Liabilities | 26.9 | 0 | 3.9 | 3.2 | 0 | 0 | 0 | 0 | 0.3 |
| Total Current Liabilities | 44.0 | 29.1 | 19.0 | 15.7 | 16.3 | 16.7 | 13.0 | 8.1 | 5.9 |
| Non-Current Liabilities | |||||||||
| Long-Term Debt | 15.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0.5 | 0.6 | 0.6 | 0.2 | 0.3 | 2.0 | 104.6 | 103.4 | 18.8 |
| Total Non-Current Liabilities | 17.1 | 20.6 | 13.1 | 14.8 | 18.0 | 15.2 | 118.2 | 116.5 | 41.0 |
| Total Liabilities | 61.0 | 49.8 | 32.1 | 30.5 | 34.4 | 31.9 | 131.2 | 124.6 | 46.9 |
| Stockholders' Equity | |||||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | (716.3) | (576.2) | (415.3) | (314.5) | (207.0) | (135.7) | (79.0) | (30.0) | (20.5) |
| Accumulated Other Comprehensive Income | 0.7 | 0.2 | 0.0 | (1.2) | (0.4) | (288.3) | (103.0) | (103.0) | (18.5) |
| Total Stockholders' Equity | 505.7 | 510.6 | 307.8 | 231.3 | 319.1 | 256.4 | (73.0) | (27.6) | (19.6) |
| Total Liabilities & Equity | 566.7 | 560.4 | 339.9 | 261.8 | 353.5 | 288.3 | 58.2 | 97.0 | 27.3 |
| Debt Metrics | |||||||||
| Total Debt | 21.4 | 24.6 | 14.7 | 16.1 | 16.4 | 0 | 0 | 0 | 0 |
| Net Debt | (38.8) | (124.7) | (234.4) | (36.2) | (136.6) | (276.7) | (49.7) | (91.8) | (23.9) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Net Income | (140.1) | (160.9) | (100.8) | (107.5) | (71.3) | (56.7) | (49.3) | (9.6) | (11.2) |
| Depreciation & Amortization | 7.6 | 6.7 | 5.7 | 3.9 | 3.0 | 1.4 | 1.0 | 0.7 | 0.6 |
| Stock-Based Compensation | 22.0 | 26.1 | 19.7 | 17.1 | 13.8 | 5.0 | 3.5 | 1.4 | 0.3 |
| Change in Working Capital | 6.2 | 0.5 | 0.6 | (1.3) | (15.5) | (0.7) | 0.3 | (8.8) | 18.5 |
| Other Non-Cash Items | (4.8) | (7.1) | (1.0) | 1.1 | 0.9 | 0.1 | 7.8 | 0.0 | 0.0 |
| Operating Cash Flow | (109.1) | (134.6) | (75.8) | (86.7) | (69.1) | (50.9) | (36.7) | (16.3) | 8.2 |
| Investing Activities | |||||||||
| Capital Expenditure | (0.5) | (3.8) | (2.8) | (11.5) | (9.1) | (1) | (3.2) | (0.4) | (0.6) |
| Acquisitions | 0 | 0 | 0 | 0 | 9.1 | 0 | 0 | 0 | 0.0 |
| Purchases of Investments | (442.8) | (467.7) | (54.8) | (153.3) | (168.6) | 0 | 0 | 0 | 0 |
| Sales/Maturities of Investments | 350.4 | 169.0 | 0 | 147.8 | 5 | 0 | 0 | 0 | 8.2 |
| Other Investing Activities | 0 | 0 | 173.3 | 0 | (9.1) | 0 | 0 | 0 | 0.0 |
| Investing Cash Flow | (93.0) | (302.4) | 115.7 | (17.1) | (172.7) | (1) | (3.2) | (0.4) | 7.7 |
| Financing Activities | |||||||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 5.8 | 8.5 | 0 | 3.8 | 0.9 | 0 | 84.6 | 0 |
| Financing Cash Flow | 113.0 | 337.2 | 156.8 | 3.1 | 118.1 | 279.0 | (2.2) | 84.6 | 0.0 |
| Cash Position | |||||||||
| Net Change in Cash | (89.1) | (99.8) | 196.8 | (100.7) | (123.7) | 227.1 | (42.1) | 67.9 | 15.9 |
| Cash at Beginning | 149.3 | 249.1 | 52.4 | 153.0 | 276.7 | 49.7 | 91.8 | 23.9 | 7.9 |
| Cash at End | 60.2 | 149.3 | 249.1 | 52.4 | 153.0 | 276.7 | 49.7 | 91.8 | 23.9 |
| Free Cash Flow | (109.1) | (138.4) | (78.6) | (98.2) | (78.2) | (51.9) | (39.9) | (16.7) | 7.7 |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 85.2 | 0.0 | 20.7 | 3.1 | 18.0 | 13.6 | 7.0 | 14.1 | 5.8 |
| Gross Profit | 77.6 | 0.0 | (76.4) | (77.1) | (43.3) | (39.4) | (31.7) | (4.2) | (7.8) |
| Operating Income | (159.5) | (187.8) | (112.9) | (110.0) | (71.3) | (56.7) | (50.8) | (10.4) | (11.3) |
| Net Income | (140.1) | (160.9) | (100.8) | (107.5) | (71.3) | (56.7) | (49.3) | (9.6) | (11.2) |
| EPS (Diluted) | -2.42 | -2.98 | -2.58 | -3.12 | -2.46 | -2.12 | -2.00 | -0.76 | -0.76 |
| Balance Sheet | |||||||||
| Cash & Equivalents | 60.2 | 149.3 | 249.1 | 52.4 | 153.0 | 276.7 | 49.7 | 91.8 | 23.9 |
| Total Assets | 566.7 | 560.4 | 339.9 | 261.8 | 353.5 | 288.3 | 58.2 | 97.0 | 27.3 |
| Total Debt | 21.4 | 24.6 | 14.7 | 16.1 | 16.4 | 0 | 0 | 0 | 0 |
| Stockholders' Equity | 505.7 | 510.6 | 307.8 | 231.3 | 319.1 | 256.4 | (73.0) | (27.6) | (19.6) |
| Cash Flow | |||||||||
| Operating Cash Flow | (109.1) | (134.6) | (75.8) | (86.7) | (69.1) | (50.9) | (36.7) | (16.3) | 8.2 |
| Capital Expenditure | (0.5) | (3.8) | (2.8) | (11.5) | (9.1) | (1) | (3.2) | (0.4) | (0.6) |
| Free Cash Flow | (109.1) | (138.4) | (78.6) | (98.2) | (78.2) | (51.9) | (39.9) | (16.7) | 7.7 |